Receptor News and Research

RSS

From espresso to filter coffee, brewing may shape what reaches your gut

A focused narrative review traces how caffeine, chlorogenic acids, and coffee fibers move through the gut and interact with microbes. The authors identify plausible links between the microbiome and liver health, but human studies have not shown that microbiome changes cause coffee’s reported metabolic benefits.

28 Sep 2026

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns

HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.

28 Sep 2026

New antibody treatment blocks immune response to prevent Alzheimer's damage

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer's disease, in which twisted clumps of a protein called tau accumulate in the brain.

28 Sep 2026

New framework maps the complex link between psychological status and cardiovascular health

CVD remains the leading cause of death worldwide, while the global burden of mental disorders continues to rise.

28 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

Prostate cancer biology helps identify hormone therapy candidates

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

27 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Long-term endocrine therapy adherence remains low after breast cancer surgery

Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates.

27 Sep 2026

Could age help explain why psychedelic studies reach different conclusions?

A cross-sectional study of 1,088 adults found that lifetime classic psychedelic use was associated with lower current anxiety and depression symptoms among younger adults, but these associations weakened with age. Mystical experiences may partly explain the age-related pattern, although the observational design cannot establish that psychedelic use caused the mental health differences.

27 Sep 2026

Toxoplasma remodels host cell surfaces to trigger invasion

At first, cholesterol and glycosylation seemed like two separate leads. As the researchers followed them, however, the pathways converged.

25 Sep 2026

Specialized immune cells bridge the nervous and immune systems

A collaborative team led by Professor Jie Zhou at Tianjin Medical University School of Basic Medicine and Professor Qiang Liu at Tianjin Medical University General Hospital published a comprehensive review in Volume 2 of the journal Immunity & Inflammation on September 8, 2026.

25 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Study identifies shared pathway driving cardiac fibrosis

Three adenosine receptor subtypes that normally send different signals were found to converge on a common pathway that activates cardiac fibroblasts, the scar-forming cells in the heart.

24 Sep 2026

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.

24 Sep 2026

New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Receptor News and Research

From espresso to filter coffee, brewing may shape what reaches your gut

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns

New antibody treatment blocks immune response to prevent Alzheimer's damage

New framework maps the complex link between psychological status and cardiovascular health

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

Research makes strong case for broader use of GLP1 drugs to protect hearts

Prostate cancer biology helps identify hormone therapy candidates

Semaglutide cuts major heart events, but researchers still cannot fully explain why

Long-term endocrine therapy adherence remains low after breast cancer surgery

Could age help explain why psychedelic studies reach different conclusions?

Toxoplasma remodels host cell surfaces to trigger invasion

Specialized immune cells bridge the nervous and immune systems

In vivo CAR-T therapy transforms customized treatments into universal medicines

Study identifies shared pathway driving cardiac fibrosis

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

Semaglutide’s heart benefits may extend beyond weight loss

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News